ArticleClinicoEconomics and outcomes research : CEOR2018

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain.

Erin Johansson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.